This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More
by Zacks Equity Research
Drug approvals for Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab
by Zacks Equity Research
Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.
Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Valneva (VALN) Reports Positive Data From COVID Vaccine Study
by Zacks Equity Research
Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.
Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA
by Zacks Equity Research
Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.
Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK
by Zacks Equity Research
Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.